Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Some patients experience nausea, constipation, or vomiting
AstraZeneca plc Boehringer Ingelheim Amgen Inc
Event Phase 2 Rate (12 mg group) Phase 2 Rate (Placebo) Nausea 45.8% 11.6% Diarrhea 33.3% 9.3% Vomiting 22.2% 2.3% Constipation 16.7% 7.0% Decreased appetite 22.2% 2.3% The nausea incidence at the highest dose a nausea percentage of roughly 46% makes it the single most reported adverse event in retatrutide clinical trials 2026 data
no amino-acid sequence Reference salt: Iodide salt CAS for iodide salt: 42464-96-0 PubChem CID for iodide record: 66522933 PubChem CID for cation: 950107 Iodide-salt formula: C10H11IN2 Iodide-salt molecular weight: 286.11 g/mol Cation formula: C10H11N2+ Cation molecular weight: 159.21 g/mol Primary research target: Nicotinamide N-methyltransferase (NNMT) Reference potency: approximately 1.2 M IC50 under a specified in-vitro assay Purity specification: 99% by HPLC, subject to lot-specific report Identity specification: Mass-spectrometry confirmation, subject to lot-specific report Product format: Lyophilized or dried research powder as stated on the lot label Release: QC-released under SaiyanMed specifications General sealed storage: 20C, protected from light and moisture Expiration: Use the date and stability statement on the lot-specific label or COA Salt Form & Molecular-Weight Basis Name Formula Molecular weight Identifier Use in calculations Do not mix salt mass and cation-equivalent mass A vial labeled by iodide-salt mass is not numerically equivalent to the same mass of free cation
Patients who were diagnosed with diabetes or overweight/obesity were separated
